Global Salivary Gland Cancer Market
Global Salivary Gland Cancer Market

Salivary Gland Cancer Comprehensive Study by Type (Parotid glands, Submandibular glands, Sublingual glands), Application (Hospitals & clinics, Medical research centers, Academic institutes, Others), Treatment (Surgery, Radiotherapy, Chemotherapy), Diagnosis (Physical exam, Imaging tests, Others) Players and Region - Global Market Outlook to 2026

Salivary Gland Cancer Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jun 2021 Edition 150 Pages 170 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Salivary gland cancer is an erratic disease in which cancer cells form in the tissues of the salivary glands. Most salivary gland tumors are benign and arise in the parotid glands. A painless salivary mass is the most general sign and is evaluated by fine-needle aspiration biopsy. Increasing incidence of salivary gland cancer is major driver for the market while other factors like increasing awareness about this disorder, the introduction of the new treatment or therapies and increasing demand from emerging markets drives the growth of the global marketThis growth is primarily driven by Increasing cases of salivary gland cancer and Growing awareness among the patients and rapidly improving healthcare infrastructure.

Globally, a noticeable market trend is evident The introduction of the new treatment or therapies . The Diseases & Therapeutic Areas sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Bayer AG (Germany), Johnson & Johnson (United States), Loxo Oncology, Inc. (United States), Merck & Co., Inc. (United States), Plexxikon Inc. (United States), Taiwan Liposome Company, Ltd. (Taiwan), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Co (United States), AstraZeneca Plc (United Kingdom) and Novartis AG (Switzerland) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 14 Dec, 2018, Merck [NYSE:MRK], known as MSD outside the United States and Canada, and privately held Antelliq Group today announced that the companies have signed a definitive agreement under which Merck will acquire Antelliq

Regulatory Insights:
The Federal Food, Drug, and Cosmetic Act is the basic food and drug law of the U.S. With numerous amendments, it is the most extensive law of its kind in the world. The law is intended to assure the consumer that foods are pure and wholesome, safe to eat, and produced under sanitary conditions; that drugs and devices are safe and effective for their intended uses; that cosmetics are safe and made from appropriate ingredients; and that all labeling and packaging is truthful, informative, and not deceptive

Market Drivers
  • Increasing cases of salivary gland cancer
  • Growing awareness among the patients and rapidly improving healthcare infrastructure

Market Trend
  • The introduction of the new treatment or therapies
  • Increasing use of insurance facilities

Restraints
  • Lack of awareness about disorder

Opportunities
Rising demand from emerging markets
Challenges
Limited availability of required healthcare facilities

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Salivary Gland Cancer Study Sheds Light on
— The Salivary Gland Cancer Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Salivary Gland Cancer industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Salivary Gland Cancer industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What are the years considered in the Salivary Gland Cancer Market?
Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026

2. Who are the key players profiled in the Salivary Gland Cancer Market?
Companies that are profiled in Global Salivary Gland Cancer Market are Bayer AG (Germany), Johnson & Johnson (United States), Loxo Oncology, Inc. (United States), Merck & Co., Inc. (United States), Plexxikon Inc. (United States), Taiwan Liposome Company, Ltd. (Taiwan), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Co (United States), AstraZeneca Plc (United Kingdom) and Novartis AG (Switzerland) etc.

3. What is Salivary Gland Cancer Market?
Salivary gland cancer is an erratic disease in which cancer cells form in the tissues of the salivary glands. Most salivary gland tumors are benign and arise in the parotid glands. A painless salivary mass is the most general sign and is evaluated by fine-needle aspiration biopsy. Increasing incidence of salivary gland cancer is major driver for the market while other factors like increasing awareness about this disorder, the introduction of the new treatment or therapies and increasing demand from emerging markets drives the growth of the global market
Report Objectives / Segmentation Covered
By Type
  • Parotid glands
  • Submandibular glands
  • Sublingual glands
By Application
  • Hospitals & clinics
  • Medical research centers
  • Academic institutes
  • Others
By Treatment
  • Surgery
  • Radiotherapy
  • Chemotherapy

By Diagnosis
  • Physical exam
  • Imaging tests
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing cases of salivary gland cancer
      • 3.2.2. Growing awareness among the patients and rapidly improving healthcare infrastructure
    • 3.3. Market Challenges
      • 3.3.1. Limited availability of required healthcare facilities
    • 3.4. Market Trends
      • 3.4.1. The introduction of the new treatment or therapies
      • 3.4.2. Increasing use of insurance facilities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Salivary Gland Cancer, by Type, Application, Treatment, Diagnosis and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Salivary Gland Cancer (Value)
      • 5.2.1. Global Salivary Gland Cancer by: Type (Value)
        • 5.2.1.1. Parotid glands
        • 5.2.1.2. Submandibular glands
        • 5.2.1.3. Sublingual glands
      • 5.2.2. Global Salivary Gland Cancer by: Application (Value)
        • 5.2.2.1. Hospitals & clinics
        • 5.2.2.2. Medical research centers
        • 5.2.2.3. Academic institutes
        • 5.2.2.4. Others
      • 5.2.3. Global Salivary Gland Cancer by: Treatment (Value)
        • 5.2.3.1. Surgery
        • 5.2.3.2. Radiotherapy
        • 5.2.3.3. Chemotherapy
      • 5.2.4. Global Salivary Gland Cancer by: Diagnosis (Value)
        • 5.2.4.1. Physical exam
        • 5.2.4.2. Imaging tests
        • 5.2.4.3. Others
      • 5.2.5. Global Salivary Gland Cancer Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Salivary Gland Cancer (Price)
      • 5.3.1. Global Salivary Gland Cancer by: Type (Price)
  • 6. Salivary Gland Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Loxo Oncology, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Plexxikon Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Taiwan Liposome Company, Ltd. (Taiwan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol-Myers Squibb Co (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AstraZeneca Plc (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Salivary Gland Cancer Sale, by Type, Application, Treatment, Diagnosis and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Salivary Gland Cancer (Value)
      • 7.2.1. Global Salivary Gland Cancer by: Type (Value)
        • 7.2.1.1. Parotid glands
        • 7.2.1.2. Submandibular glands
        • 7.2.1.3. Sublingual glands
      • 7.2.2. Global Salivary Gland Cancer by: Application (Value)
        • 7.2.2.1. Hospitals & clinics
        • 7.2.2.2. Medical research centers
        • 7.2.2.3. Academic institutes
        • 7.2.2.4. Others
      • 7.2.3. Global Salivary Gland Cancer by: Treatment (Value)
        • 7.2.3.1. Surgery
        • 7.2.3.2. Radiotherapy
        • 7.2.3.3. Chemotherapy
      • 7.2.4. Global Salivary Gland Cancer by: Diagnosis (Value)
        • 7.2.4.1. Physical exam
        • 7.2.4.2. Imaging tests
        • 7.2.4.3. Others
      • 7.2.5. Global Salivary Gland Cancer Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Salivary Gland Cancer (Price)
      • 7.3.1. Global Salivary Gland Cancer by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Salivary Gland Cancer: by Type(USD Million)
  • Table 2. Salivary Gland Cancer Parotid glands , by Region USD Million (2015-2020)
  • Table 3. Salivary Gland Cancer Submandibular glands , by Region USD Million (2015-2020)
  • Table 4. Salivary Gland Cancer Sublingual glands , by Region USD Million (2015-2020)
  • Table 5. Salivary Gland Cancer: by Application(USD Million)
  • Table 6. Salivary Gland Cancer Hospitals & clinics , by Region USD Million (2015-2020)
  • Table 7. Salivary Gland Cancer Medical research centers , by Region USD Million (2015-2020)
  • Table 8. Salivary Gland Cancer Academic institutes , by Region USD Million (2015-2020)
  • Table 9. Salivary Gland Cancer Others , by Region USD Million (2015-2020)
  • Table 10. Salivary Gland Cancer: by Treatment(USD Million)
  • Table 11. Salivary Gland Cancer Surgery , by Region USD Million (2015-2020)
  • Table 12. Salivary Gland Cancer Radiotherapy , by Region USD Million (2015-2020)
  • Table 13. Salivary Gland Cancer Chemotherapy , by Region USD Million (2015-2020)
  • Table 14. Salivary Gland Cancer: by Diagnosis(USD Million)
  • Table 15. Salivary Gland Cancer Physical exam , by Region USD Million (2015-2020)
  • Table 16. Salivary Gland Cancer Imaging tests , by Region USD Million (2015-2020)
  • Table 17. Salivary Gland Cancer Others , by Region USD Million (2015-2020)
  • Table 18. South America Salivary Gland Cancer, by Country USD Million (2015-2020)
  • Table 19. South America Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 20. South America Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 21. South America Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 22. South America Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 23. Brazil Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 24. Brazil Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 25. Brazil Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 26. Brazil Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 27. Argentina Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 28. Argentina Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 29. Argentina Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 30. Argentina Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 31. Rest of South America Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 32. Rest of South America Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 33. Rest of South America Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 34. Rest of South America Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 35. Asia Pacific Salivary Gland Cancer, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 37. Asia Pacific Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 38. Asia Pacific Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 39. Asia Pacific Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 40. China Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 41. China Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 42. China Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 43. China Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 44. Japan Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 45. Japan Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 46. Japan Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 47. Japan Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 48. India Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 49. India Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 50. India Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 51. India Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 52. South Korea Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 53. South Korea Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 54. South Korea Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 55. South Korea Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 56. Taiwan Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 57. Taiwan Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 58. Taiwan Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 59. Taiwan Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 60. Australia Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 61. Australia Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 62. Australia Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 63. Australia Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 68. Europe Salivary Gland Cancer, by Country USD Million (2015-2020)
  • Table 69. Europe Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 70. Europe Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 71. Europe Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 72. Europe Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 73. Germany Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 74. Germany Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 75. Germany Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 76. Germany Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 77. France Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 78. France Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 79. France Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 80. France Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 81. Italy Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 82. Italy Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 83. Italy Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 84. Italy Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 85. United Kingdom Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 86. United Kingdom Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 87. United Kingdom Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 88. United Kingdom Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 89. Netherlands Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 90. Netherlands Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 91. Netherlands Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 92. Netherlands Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 93. Rest of Europe Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 94. Rest of Europe Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 95. Rest of Europe Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 96. Rest of Europe Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 97. MEA Salivary Gland Cancer, by Country USD Million (2015-2020)
  • Table 98. MEA Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 99. MEA Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 100. MEA Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 101. MEA Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 102. Middle East Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 103. Middle East Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 104. Middle East Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 105. Middle East Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 106. Africa Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 107. Africa Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 108. Africa Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 109. Africa Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 110. North America Salivary Gland Cancer, by Country USD Million (2015-2020)
  • Table 111. North America Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 112. North America Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 113. North America Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 114. North America Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 115. United States Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 116. United States Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 117. United States Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 118. United States Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 119. Canada Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 120. Canada Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 121. Canada Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 122. Canada Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 123. Mexico Salivary Gland Cancer, by Type USD Million (2015-2020)
  • Table 124. Mexico Salivary Gland Cancer, by Application USD Million (2015-2020)
  • Table 125. Mexico Salivary Gland Cancer, by Treatment USD Million (2015-2020)
  • Table 126. Mexico Salivary Gland Cancer, by Diagnosis USD Million (2015-2020)
  • Table 127. Salivary Gland Cancer: by Type(USD/Units)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Salivary Gland Cancer: by Type(USD Million)
  • Table 139. Salivary Gland Cancer Parotid glands , by Region USD Million (2021-2026)
  • Table 140. Salivary Gland Cancer Submandibular glands , by Region USD Million (2021-2026)
  • Table 141. Salivary Gland Cancer Sublingual glands , by Region USD Million (2021-2026)
  • Table 142. Salivary Gland Cancer: by Application(USD Million)
  • Table 143. Salivary Gland Cancer Hospitals & clinics , by Region USD Million (2021-2026)
  • Table 144. Salivary Gland Cancer Medical research centers , by Region USD Million (2021-2026)
  • Table 145. Salivary Gland Cancer Academic institutes , by Region USD Million (2021-2026)
  • Table 146. Salivary Gland Cancer Others , by Region USD Million (2021-2026)
  • Table 147. Salivary Gland Cancer: by Treatment(USD Million)
  • Table 148. Salivary Gland Cancer Surgery , by Region USD Million (2021-2026)
  • Table 149. Salivary Gland Cancer Radiotherapy , by Region USD Million (2021-2026)
  • Table 150. Salivary Gland Cancer Chemotherapy , by Region USD Million (2021-2026)
  • Table 151. Salivary Gland Cancer: by Diagnosis(USD Million)
  • Table 152. Salivary Gland Cancer Physical exam , by Region USD Million (2021-2026)
  • Table 153. Salivary Gland Cancer Imaging tests , by Region USD Million (2021-2026)
  • Table 154. Salivary Gland Cancer Others , by Region USD Million (2021-2026)
  • Table 155. South America Salivary Gland Cancer, by Country USD Million (2021-2026)
  • Table 156. South America Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 157. South America Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 158. South America Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 159. South America Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 160. Brazil Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 161. Brazil Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 162. Brazil Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 163. Brazil Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 164. Argentina Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 165. Argentina Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 166. Argentina Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 167. Argentina Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 168. Rest of South America Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 169. Rest of South America Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 170. Rest of South America Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 171. Rest of South America Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 172. Asia Pacific Salivary Gland Cancer, by Country USD Million (2021-2026)
  • Table 173. Asia Pacific Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 174. Asia Pacific Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 175. Asia Pacific Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 176. Asia Pacific Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 177. China Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 178. China Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 179. China Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 180. China Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 181. Japan Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 182. Japan Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 183. Japan Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 184. Japan Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 185. India Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 186. India Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 187. India Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 188. India Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 189. South Korea Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 190. South Korea Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 191. South Korea Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 192. South Korea Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 193. Taiwan Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 194. Taiwan Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 195. Taiwan Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 196. Taiwan Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 197. Australia Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 198. Australia Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 199. Australia Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 200. Australia Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 205. Europe Salivary Gland Cancer, by Country USD Million (2021-2026)
  • Table 206. Europe Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 207. Europe Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 208. Europe Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 209. Europe Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 210. Germany Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 211. Germany Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 212. Germany Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 213. Germany Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 214. France Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 215. France Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 216. France Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 217. France Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 218. Italy Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 219. Italy Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 220. Italy Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 221. Italy Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 222. United Kingdom Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 223. United Kingdom Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 224. United Kingdom Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 225. United Kingdom Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 226. Netherlands Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 227. Netherlands Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 228. Netherlands Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 229. Netherlands Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 230. Rest of Europe Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 231. Rest of Europe Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 232. Rest of Europe Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 233. Rest of Europe Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 234. MEA Salivary Gland Cancer, by Country USD Million (2021-2026)
  • Table 235. MEA Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 236. MEA Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 237. MEA Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 238. MEA Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 239. Middle East Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 240. Middle East Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 241. Middle East Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 242. Middle East Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 243. Africa Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 244. Africa Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 245. Africa Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 246. Africa Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 247. North America Salivary Gland Cancer, by Country USD Million (2021-2026)
  • Table 248. North America Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 249. North America Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 250. North America Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 251. North America Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 252. United States Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 253. United States Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 254. United States Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 255. United States Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 256. Canada Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 257. Canada Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 258. Canada Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 259. Canada Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 260. Mexico Salivary Gland Cancer, by Type USD Million (2021-2026)
  • Table 261. Mexico Salivary Gland Cancer, by Application USD Million (2021-2026)
  • Table 262. Mexico Salivary Gland Cancer, by Treatment USD Million (2021-2026)
  • Table 263. Mexico Salivary Gland Cancer, by Diagnosis USD Million (2021-2026)
  • Table 264. Salivary Gland Cancer: by Type(USD/Units)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Salivary Gland Cancer: by Type USD Million (2015-2020)
  • Figure 5. Global Salivary Gland Cancer: by Application USD Million (2015-2020)
  • Figure 6. Global Salivary Gland Cancer: by Treatment USD Million (2015-2020)
  • Figure 7. Global Salivary Gland Cancer: by Diagnosis USD Million (2015-2020)
  • Figure 8. South America Salivary Gland Cancer Share (%), by Country
  • Figure 9. Asia Pacific Salivary Gland Cancer Share (%), by Country
  • Figure 10. Europe Salivary Gland Cancer Share (%), by Country
  • Figure 11. MEA Salivary Gland Cancer Share (%), by Country
  • Figure 12. North America Salivary Gland Cancer Share (%), by Country
  • Figure 13. Global Salivary Gland Cancer: by Type USD/Units (2015-2020)
  • Figure 14. Global Salivary Gland Cancer share by Players 2020 (%)
  • Figure 15. Global Salivary Gland Cancer share by Players (Top 3) 2020(%)
  • Figure 16. Global Salivary Gland Cancer share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 20. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 21. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 22. Loxo Oncology, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Loxo Oncology, Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Plexxikon Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Plexxikon Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Taiwan Liposome Company, Ltd. (Taiwan) Revenue, Net Income and Gross profit
  • Figure 29. Taiwan Liposome Company, Ltd. (Taiwan) Revenue: by Geography 2020
  • Figure 30. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2020
  • Figure 32. Bristol-Myers Squibb Co (United States) Revenue, Net Income and Gross profit
  • Figure 33. Bristol-Myers Squibb Co (United States) Revenue: by Geography 2020
  • Figure 34. AstraZeneca Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. AstraZeneca Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 36. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 37. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 38. Global Salivary Gland Cancer: by Type USD Million (2021-2026)
  • Figure 39. Global Salivary Gland Cancer: by Application USD Million (2021-2026)
  • Figure 40. Global Salivary Gland Cancer: by Treatment USD Million (2021-2026)
  • Figure 41. Global Salivary Gland Cancer: by Diagnosis USD Million (2021-2026)
  • Figure 42. South America Salivary Gland Cancer Share (%), by Country
  • Figure 43. Asia Pacific Salivary Gland Cancer Share (%), by Country
  • Figure 44. Europe Salivary Gland Cancer Share (%), by Country
  • Figure 45. MEA Salivary Gland Cancer Share (%), by Country
  • Figure 46. North America Salivary Gland Cancer Share (%), by Country
  • Figure 47. Global Salivary Gland Cancer: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Bayer AG (Germany)
  • Johnson & Johnson (United States)
  • Loxo Oncology, Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Plexxikon Inc. (United States)
  • Taiwan Liposome Company, Ltd. (Taiwan)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Bristol-Myers Squibb Co (United States)
  • AstraZeneca Plc (United Kingdom)
  • Novartis AG (Switzerland)
Additional players considered in the study are as follows:
Pfizer Inc (United States) , Daiichi Sankyo Co (Japan) , Astellas Pharma Inc (Japan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation